Full text is available at the source.
ED-71 alleviates OVX-induced osteoporosis by inhibiting macrophage senescence through SIRT1/PGC-1α pathway: A potential therapeutic approach
ED-71 may reduce bone loss after ovaries are removed by stopping aging in immune cells through the SIRT1/PGC-1α pathway
AI simplified
Abstract
Eldecalcitol (ED-71) improved bone mass and aging in ovariectomized mice with postmenopausal osteoporosis.
- Postmenopausal osteoporosis is linked to estrogen deficiency, aging, and oxidative stress.
- Cellular senescence in macrophages disrupts bone homeostasis, affecting bone marrow stromal cells' (BMSCs) ability to form bone.
- Senescent macrophages impair the osteogenic differentiation of BMSCs.
- Eldecalcitol (ED-71) and 17β-Estradiol (E2) reduced markers of cellular senescence in macrophages.
- The anti-senescence effects of ED-71 may involve the SIRT1/PGC-1α signaling pathway.
AI simplified